Skip to main content
    R

    Rezolute Inc (RZLT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.88
    +0.24 (+6.59%)

    Market Cap: $352.07M

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(20/30)
    Avg Surprise
    +2.16%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.21 - $-0.14
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.13-30.9%
    60d ago$-0.13-30.9%
    30d ago$-0.13-30.9%
    7d ago$-0.170.0%
    Current$-0.17
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.17$-0.21 - $-0.14--8
    0
    4
    30d
    		-
    Sep 26
    Reported Nov 5
    		$-0.18$-0.18$-0.21 - $-0.15+0.00%Beat8
    0
    4
    30d
    		+0.0%
    Jun 26
    Reported Sep 24
    		$-0.20$-0.14$-0.17 - $-0.11-42.86%Miss8
    4
    3
    30d
    		+23.1%
    Mar 26
    Reported May 12
    		$-0.16$-0.17$-0.24 - $-0.09+7.99%Beat7
    1
    4
    30d
    		+42.4%
    Dec 25
    Reported Feb 12
    		$-0.22$-0.18$-0.21 - $-0.15-22.22%Miss7
    4
    1
    30d
    		+0.0%
    Sep 25
    Reported Nov 6
    		$-0.18$-0.26$-0.28 - $-0.26+30.77%Beat6
    0
    2
    30d
    		+18.2%
    Jun 25
    Reported Sep 17
    		$-0.26$-0.21$-0.29 - $-0.20-21.89%Miss8
    No revisions (30d)
    		+40.9%
    Mar 25
    Reported May 13
    		$-0.27$-0.24$-0.27 - $-0.21-12.50%Miss6
    1
    0
    30d
    		+20.6%
    Dec 24
    Reported Feb 12
    		$-0.22$-0.26$-0.30 - $-0.23+15.38%Beat7
    1
    0
    30d
    		+18.5%
    Sep 24
    Reported Nov 7
    		$-0.22$-0.34$-0.44 - $-0.25+35.29%Beat6
    No revisions (30d)
    		+21.4%
    Jun 24
    Reported Sep 19
    		$-0.44$-0.33$-0.42 - $-0.23-33.33%Miss9
    No revisions (30d)
    		-76.0%
    Mar 24
    Reported May 15
    		$-0.34$-0.32$-0.36 - $-0.19-6.25%Miss7
    0
    1
    30d
    		-13.3%
    Dec 23
    Reported Feb 13
    		$-0.27$-0.29$-0.34 - $-0.28+6.90%Beat3
    No revisions (30d)
    		-3.8%

    Key Metrics

    Valuation
    P/E Ratio-5.14EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-59.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio9.92xQuick Ratio9.92x
    Trading Statistics
    Beta0.62Avg Volume1.35M
    52-Week High$11.4652-Week Low$1.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.96
    SMA 20$3.98
    SMA 50$4.14
    SMA 200$3.91
    EMA 10$3.91
    EMA 20$3.98
    EMA 50$4.14
    EMA 200$4.35

    MACD

    Line: -0.09Signal: -0.09Hist: -0.00

    ADX

    ADX: 14.3+DI: 21.5-DI: 26.6

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down44.0
    PSAR$4.32

    Bollinger Bands

    Upper Band$4.62
    Lower Band$3.34
    %B Position3212%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    46.2

    Momentum Oscillators

    Stoch %K43.1
    Stoch %D50.1
    Williams %R-59.2
    ROC (10d)0.6%
    Momentum0.03
    CCI (20d)-57.3
    MFI (14d)60.6

    Volatility Measures

    ATR (14d)$0.30(7.8%)
    StdDev (20d)0.32
    Hist Vol77.0%(High)

    Volume Flow

    VWAP$3.79
    OBV-8.7M
    AD Line69.2M
    CMF (20d)-0.098

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.2x
    VWMA (20d)$3.97

    Pivot Points

    R3$4.29
    R2$4.13
    R1$3.89
    Pivot Point$3.72
    S1$3.48
    S2$3.32
    S3$3.07

    Advanced Oscillators

    TSI-9.52
    Ultimate Osc40.0
    KST-58.77

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0N/A$0$0$0$46,000$0$0$0$58,000$0$0
    Cost of Revenue$0N/A$0$0$0$8,000$0$0$0$7,000$0$0
    Gross Profit$0N/A$0$0$0$-8,000$0$0$0$51,000$0$0
    Operating Expenses$19.39M$21.56M$17.37M$24.22M$19.82M$25.85M$20.02M$17.08M$16.94M$23.10M$16.21M$15.19M
    R&D$12.81M$14.89M$11.41M$14.35M$13.15M$20.86M$15.28M$12.63M$12.75M$19.09M$12.40M$12.04M
    SG&A$6.58M$6.67M$5.95M$9.87M$6.67M$4.99M$4.74M$4.45M$4.19M$4.01M$3.81M$3.15M
    Operating Income$-19,385,000$-21,562,000$-17,366,000$-24,221,000$-19,817,000$-25,850,000$-20,023,000$-17,080,000$-16,941,000$-23,102,000$-16,213,000$-15,194,000
    Interest Income$918,000$1.06M$1.20M$1.45M$1.68M$1.45M$1.11M$1.34M$1.58M$1.04M$1.12M$1.30M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$837,000$0
    Income Before Tax$-18,487,000$-20,491,000$-16,171,000$-22,774,000$-18,150,000$-24,390,000$-18,914,000$-15,730,000$-15,378,000$-22,976,000$-17,050,000$-13,909,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,487,000$-20,491,000$-16,171,000$-22,774,000$-18,150,000$-24,390,000$-18,914,000$-15,730,000$-15,378,000$-22,976,000$-17,050,000$-13,909,000
    EBITDA$-19,880,000$-22,010,000$-17,839,000$-24,927,000$-20,623,000$-26,177,000$-20,524,000$-17,789,000$-17,782,000$-24,747,000$-19,082,000$-17,356,000
    EBIT$-19,405,000$-21,562,000$-17,366,000$-24,221,000$-19,832,000$-25,850,000$-20,029,000$-17,074,000$-16,956,000$-24,017,000$-18,172,000$-15,212,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RZLT

    RZLT Valuation and Fair Value

    P/E
    -5.1x
    P/B
    4.7x
    See GNG's fair value

    RZLT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -59.0%

    RZLT Competitors

    CompanyTicker
    Zura Bio Limited Class A Ordinary SharesZURA
    Contineum Therapeutics, Inc. Class A Common StockCTNM
    Orthofix Medical IncOFIX
    Viemed Healthcare IncVMD
    Fennec Pharmaceuticals IncFENC
    Orchestra BioMed Holdings Inc.OBIO
    Wellgistics Health, Inc. Common StockWGRX
    Semler Scientific IncSMLR

    Sector: Healthcare

    RZLT Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    2
    Buy
    8
    Hold
    1
    Sell
    0
    Strong Sell
    0

    RZLT Bull Case vs Bear Case

    Bull case

    • 90.9% of RZLT's analyst ratings are Buy or Strong Buy.

    Bear case

    • RZLT beat EPS estimates in 37.5% of its last 8 reported quarters.

    RZLT Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -5.7%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.17
    Estimate revisions (30 days, fiscal period ending Dec 31, 2026)
    0 up, 4 down

    RZLT Earnings Date

    RZLT reports Feb 10, 2027. The date is estimated.

    RZLT ETF Holders

    GNG tracks 8 ETFs that hold RZLT. The largest weights:

    1. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.03% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.02% of the fund
    3. Vanguard Extended Market Index Fund ETF Shares (VXF), 0.01% of the fund
    4. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    5. Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
    Open the ETF Stock Exposure tool for RZLT

    See insider activity

    Frequently Asked Questions About RZLT

    When does RZLT report earnings?

    Rezolute Inc (RZLT) is expected to report earnings on Feb 10, 2027.

    Does RZLT pay dividends?

    Rezolute Inc (RZLT) does not currently pay a regular dividend.

    What is RZLT's market cap?

    Rezolute Inc (RZLT) has a market capitalization of $352.07M with a current stock price of $3.88.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In